Public-registry site landscape for NCT07730632, a IgAN - IgA Nephropathy study sponsored by Qilu Pharmaceutical Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07730632 (registry record) |
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Condition(s) | IgAN - IgA Nephropathy; Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN); C3 Glomerulopathy (C3G); Primary Membranous Nephropathy |
| Phase | PHASE2 |
| Listed sites | 1 |
| Site countries | China |
At Peking University First Hospital — one of the facilities listed on this trial — 11 other studies are actively recruiting IgAN - IgA Nephropathy patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Eichor generates a preliminary site-risk snapshot for NCT07730632 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →